New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
23:40 EDTRNDY, WPRT, ESRX, TITN, CELG, BEAM, P, CMG, KORS, STO, TSCO, AGN, SLE, AUQ, DRI, GLD, SHW, HD, COV, CHKJim Cramer's "Mad Money"
Jim Cramer said, "2012 is no longer about global economic crisis, it's about buying stock in the companies you love." Cramer said he's no longer sweating the details of every story that hits the news wires. Because the big-money players, those who would sell on every bit of negative news, are simply no longer a part of this market. They have been replaced by good old-fashioned individual investors. When companies break up, investors win, Cramer reminded viewers, as he highlighted yet another corporate breakup story, Sara Lee (SLE). He said that shares of Sara Lee should follow in the footsteps of Beam (BEAM) and Covidien (COV), two other breakup stocks, which headed markedly higher. Sara Lee is offering a $3-a-share special dividend to shareholders when the breakup occurs. Additionally, recent analysis of Sara Lee's various components values the stock 22% higher than where it trades today. Sara Lee plans to update shareholders on its progress at an investors meeting on June 5. Investing in Sara Lee will be a slow climb, said Cramer, which is why he would use recent weakness in the stock to get in at attractive prices. Continuing with his week-long series of great American growth stocks, Cramer turned the spotlight onto Allergan (AGN). It is not only a health care company that treats eye problems and migraines, but it is also a leader in medical aesthetics, including Botox and great implants. Cramer said that Allergan has multiple years of growth ahead of it. Its end markets are huge. Also, Allergan is highly competitive in every arena in which it enters and the company pays a tiny dividend. Shares trade for just 19x earnings and the company has a 14% long-term growth rate. Giving investors another great American growth stock, Cramer also highlighted Celgene (CELG), another stock just off its 52-week high. Celgene has one of the fastest growth rates in its sector, said Cramer, and also huge market potential as a host of new products and new applications for existing products are chugging toward FDA approval. Internationally, the company is a powerhouse. Cramer said that while Celgene is unlikely to offer a dividend anytime soon, the company has done a few well-timed stock buybacks to reward shareholders. Celgene sports a rock-solid balance sheet. Celgene trades at just 13.8x next year's earnings, despite the company's 24% growth rate. NO HUDDLE OFFENSE: Cramer said that the tailwinds are all lining up for a great quarter at Home Depot (HD), and he would be a buyer of the stock, even up near its 52-week high. Case-in-point: Tractor Supply (TSCO) announced sales that are double what analysts are expecting and Titan Machinery (TITN) pre-announced strong earnings, followed by Sherwin-Williams (SHW) announcing sales up by 20%. LIGHTNING ROUND: (Bullish) STO; ESRX; GLD; KORS; WPRT; DRI; CMG; RNDY. (Bearish) AUQ; P; CHK. Reference Link
News For SLE;BEAM;COV;AGN;CELG;HD;TSCO;TITN;SHW;STO;ESRX;GLD;KORS;WPRT;DRI;CMG;RNDY;AUQ;P;CHK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
November 17, 2014
05:59 EDTGLDSPDR Gold Trust overall implied volatility at 19; 26-week average is 16
November 16, 2014
18:57 EDTPSirius loses request to dismiss Turtles' lawsuit on pre-1972 songs, NYT says
Subscribe for More Information
14:02 EDTAGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:39 EDTESRXBerkshire Hathaway gives quarterly update on stakes
Subscribe for More Information
16:21 EDTPOn The Fly: Closing Wrap
Subscribe for More Information
15:47 EDTSTOStatoil to hold a mini-seminar
Subscribe for More Information
14:53 EDTESRXCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:58 EDTPOn The Fly: Midday Wrap
Subscribe for More Information
12:43 EDTCOVMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTCOVMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
11:22 EDTPPandora rallies after CEO share purchase
The stock is being pushed higher by word that the CEO of the company made a purchase of 25,000 shares following the recent lows at $17.55. At the current price of $20.97 resistance is at the bottom of the bearish gap down in price from October 24th at $21.17. A move higher puts the shares back into the gap for a bullish gap fill. Resistance would be at $22.48 thereafter. Support is at $20.31. Approximately 10% of the float is short which is likely contributing to a squeeze higher.
11:05 EDTPPandora jumps following CEO share purchase
Shares of Pandora (P) are rallying after the company's CEO disclosed that he had bought 25,000 shares of the company's stock. WHAT'S NEW: In a regulatory filing last night, Pandora CEO Brian McAndrews disclosed that he had bought 25,000 of the company's shares on Wenesday at a price of $18.58 per share. McAndrews now owns over 475,000 shares of the stock, according to the filing. ANALYST REACTION: In a note to investors, Stifel analyst Scott Devitt wrote that McAndrews purchased the stock using his own personal funds. According to the analyst, it is quite rare for CEOs to take such an action. McAndrews' purchase of the stock was "a strong vote of confidence" in the company, Devitt contended. He kept a $29 price target and Buy rating on the shares. WHAT'S NOTABLE: Pandora announced that it would hold a conference call next Tuesday to discuss proceedings before the Copyright Royalty Board. The board will determine the company's new royalty structure by December 2015, Devitt wrote. PRICE ACTION: In mid-morning trading, Pandora climbed $2.30, or 12.5%, to $20.75.
10:00 EDTHDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTPActive equity options trading
Subscribe for More Information
09:34 EDTHDHome Depot downgraded to Hold from Buy at Zelman
08:18 EDTPPandora CEO share purchases a significant vote of confidence, says Stifel
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:09 EDTGLDSPDR Gold Trust overall implied volatility at 18; 26-week average is 16
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use